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Abstract
Background
Pancreatic cancer has poor prognosis and existing interventions provide a modest benefit.
Statin has anti-cancer properties that might enhance survival in pancreatic cancer patients.
We sought to determine whether statin treatment after cancer diagnosis is associated with
longer survival in those with pancreatic ductal adenocarcinoma (PDAC).
Methods
We analyzed data on 7813 elderly patients with PDAC using the linked Surveillance, Epide-
miology, and End Results (SEER) - Medicare claims files. Information on the type, intensity
and duration of statin use after cancer diagnosis was extracted from Medicare Part D. We
treated statin as a time-dependent variable in a Cox regression model to determine the as-
sociation with overall survival adjusting for follow-up, age, sex, race, neighborhood income,
stage, grade, tumor size, pancreatectomy, chemotherapy, radiation, obesity, dyslipidemia,
diabetes, chronic pancreatitis and chronic obstructive pulmonary disease (COPD).
Results
Overall, statin use after cancer diagnosis was not significantly associated with survival
when all PDAC patients were considered (HR = 0.94, 95%CI 0.89, 1.01). However, statin
use after cancer diagnosiswas associated with a 21% reduced hazard of death (Hazard
ratio = 0.79, 95% confidence interval (CI) 0.67, 0.93) in those with grade I or II PDAC and to
a similar extent in those who had undergone a pancreatectomy, in those with chronic pan-
creatitis and in those who had not been treated with statin prior to cancer diagnosis.
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Conclusions
We found that statin treatment after cancer diagnosis is associated with enhanced survival
in patients with low-grade, resectable PDAC.
Introduction
The prognosis for persons with pancreatic cancer remains poor, with an estimated 5-year sur-
vival probability of 6%.[1] With the recent increase in incidence [1], pancreatic cancer is pro-
jected to be the 2nd leading cause of cancer death in the U.S. by year 2020 [2].
Existing interventions for pancreatic cancer, including surgical resection and gemcitabine
treatment are limited in scope and provide only a modest benefit [3]; and there remains a need
for alternative therapeutic agents that improve pancreatic cancer outcomes. Mechanistic stud-
ies demonstrate that HMG-CoA reductase inhibitors, or statins, not only mitigate elevated cho-
lesterol levels, but also appear to have anti-cancer properties through inhibition of post-
translational modification of key proteins involved in tumor proliferation and metastasis [4].
In line with the molecular effects, an observational study of 250 pancreatic cancer patients
found that statin treatment is associated with improved survival among diabetics [5], although
a clinical trial of simvastatin in 114 gemcitabine-treated patients with advanced pancreatic can-
cer observed no effect of a 3-week statin regimen on survival [6]. Both of these studies were
limited in sample size and not population-based. Furthermore, questions regarding the vari-
ability in effect by statin type and intensity, as well as cancer stage and interventions remain
unexplored.
Given the dismal prognosis for pancreatic cancer patients and the widely accepted tolerabili-
ty of statins, we examined the hypothesis that statin treatment may provide a survival advan-
tage among an elderly population with pancreatic adenocarcinoma using the linked
Surveillance, Epidemiology, and End Results (SEER)—Medicare claims files. Special advan-
tages of these linked data include the provision of a nationally representative sample of cancer
patients in the U.S., as well as a comprehensive record of type, timing and intensity of statin
prescriptions filled by the cancer patients.
Methods
Study population
We conducted a retrospective cohort study of elderly pancreatic cancer patients represented in
the SEER-Medicare database. SEER is a national program of 18 regional or state-wide cancer
registries in the U.S. Since 1991, the Centers for Medicaid and Medicare Services (CMS) has
partnered with SEER to link the cancer registries and claims-based data in Medicare-enrolled
populations to facilitate health services research [7]. Starting in 2007, CMS also began to link
data fromMedicare Part D, a newly implemented insurance program for prescription drug
coverage. As of 2014, SEER Program data were available for patients diagnosed with cancer
through 2009 and prescription data on Medicare Part D enrollees were available starting in
2007; therefore, patients with primary pancreatic adenocarcinoma diagnosed from 2007 to
2009 were selected for the analysis. We restricted the study population to patients who were
continuously enrolled in Medicare Part D beginning 3 months before cancer diagnosis to death
or end of follow-up (December 31st, 2010). This design permitted the investigation of out-
comes among patients exposed to statins following cancer diagnosis as well as the potential
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modifying effect of statin exposure for up to 3 months before cancer diagnosis. As we wished
to capture information on comorbidities present prior to cancer diagnosis and cancer-related
procedures present in inpatient and outpatient claims files, we further restricted the study pop-
ulation to persons who were continuously enrolled in Medicare Parts A and B from 12 months
before their cancer diagnosis until death or end of follow-up. A total of 17044 pancreatic cancer
cases among elderly aged 65 years or older were reported to SEER in 2007–2009. Excluding pa-
tients who did not have primary pancreatic adenocarcinoma of malignant form, patients who
were diagnosed at autopsy or had unknown time of diagnosis, and those without continual en-
rollment in Medicare A, B and D, 7813 patients remained and made up the final analytic popu-
lation for the present study. (Fig. 1)
Data
SEER registries data
Among patients with ‘pancreas’ as the primary site of cancer in the SEER registries, adenocarci-
noma types were specifically selected for using ICD-O-3 histology codes: 8000, 8010, 8020,
8021, 8022, 8140, 8141, 8211, 8230, 8500, 8521, 8050, 8260, 8441, 8450, 8453, 8470, 8471, 8472,
8473, 8480, 8481, 8503. Patients were characterized by demographic factors including, age, sex,
race, and neighborhood income, and clinical data, including grade, stage and tumor size at di-
agnosis. Only cases confirmed by microscopy, laboratory markers, radiography, and/or direct
visual inspection were selected for the analyses. The outcome of interest was overall survival
since the time of cancer diagnosis to death or December 31st, 2010, the last date of available
Medicare claims data.
Fig 1. Selection of Medicare patients diagnosed with primary pancreatic adenocarcinoma in 2007–
2009.
doi:10.1371/journal.pone.0121783.g001
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Medicare claims data
Exposure to statins after cancer diagnosis was assessed both as a binary variable (ever use after
cancer diagnosis vs. never use), and as an ordinal variable (high, moderate, low intensity vs.
never use). High, moderate and low intensity statin therapy followed the categorizations set
forth by the American Heart Association and the American College of Cardiologists [8]. We
also investigated the associations of statin use with survival by statin potency and lipophilicity:
high potency statins (atorvastatin, rosuvastatin, simvastatin) or low potency statins (fluvasta-
tin, lovastatin, pravastatin), lipophilic statins (atorvastatin, fluvastatin, lovastatin, simvastatin)
or hydrophilic statins (pravastatin, rosuvastatin).
Surgical resection of the pancreas was determined through the Medicare inpatient files
using ICD9 procedure codes: 52.6, 52.7, 52.51, 52.52, 52.53, 52.59. Dyslipidemia, diabetes or
impaired glucose tolerance (IGT), obesity, chronic pancreatitis, and chronic obstructive pul-
monary disease (COPD) were extracted through the Medicare claims files from inpatient and
outpatient records and were defined using the following ICD9 diagnostic codes: Diabetes melli-
tus / Impaired glucose tolerance: 250.xx, 790.2, 790.21, 790.22, 790.29, Overweight, Obesity:
278.0, 278.1, 278.00, 278.01, 278.02, 783.1, v77.8, Dyslipidemia: 272.0, 272.1, 272.2, 272.4,
272.5, 272.9, COPD: 491.0, 491.1, 491.20, 491.21, 491.8, 491.9, 492.0, 492.8, 494, 494.0, 494.1,
496, chronic pancreatitis: 577.1. Due to the lack of data on smoking, an established risk factor
for PDAC, we included COPD as a proxy variable for smoking-related diseases. We also ob-
tained information regarding chemotherapy and radiation treatment through the Medicare
files using commonly used ICD9 and Current Procedural Terminology codes [9].
Statistical analyses
The distributions of demographic, pathologic, and clinical characteristics were compared be-
tween statin users and non-users by Chi-squared analyses. We estimated the median survival
times from diagnosis to death by statin use using Kaplan-Meier analyses, testing for differences
by the log-rank test. We examined the relationship between statin use and survival in PDAC
patients through several Cox regression approaches. First we modeled the relationship between
ever use of statin after cancer diagnosis as a non-time-dependent variable, i.e. patients who
ever used statin after cancer diagnosis were classified as statin users as that from the time of
cancer diagnosis. Next, we analyzed statin as a time-dependent covariate given the potential for
immortal time bias, that is, the extended length of survival time between cancer diagnosis and
statin exposure during which death could not have occurred [10]. To prevent this bias from af-
fecting our results we classified 1) patients who were already on statin as statin users from the
time of cancer diagnosis and 2) patients who were not on statin at the time of cancer diagnosis,
but filled a statin prescription after cancer diagnosis as non-users until they filled the statin pre-
scription. We then evaluated the independent association of statin use after cancer diagnosis
and survival by sequentially adding the following potential confounders: 1) age, sex, race,
neighborhood income, 2) stage, grade and tumor size, 3) resection radiation and chemothera-
py, 4) obesity, dyslipidemia, diabetes/IGT, chronic pancreatitis and COPD. Receipt of a pan-
createctomy, chemotherapy or radiation were also incorporated as time-dependent covariates
when the intervention was first indicated on or after cancer diagnosis based on dates reported
in Medicare claims files. We considered chemotherapy and radiation administered within 6
months of the pancreatic cancer diagnosis as relevant interventions for the primary cancer. In
addition, to evaluate the influence of reverse causation, that is, the impact of end-of-life deci-
sions on statin use, we conducted a multivariable model in which time-dependent statin expo-
sure was lagged by 2 months prior to the time of death and in a contemporaneous period in
those who were alive. In this analysis, we restricted the population to those with at least 2
Statin and Pancreatic Cancer Survival
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months survival. We performed stratified analyses by selected variables to identify modifiers of
the statin effect: age group, summary stage, grade, tumor size, resection, chemotherapy, dyslipi-
demia and diabetes. Heterogeneity in effect was tested by an interaction term with the time-de-
pendent statin variable in the multivariable models. The multivariable models examining the
interactions were based on the analysis that incorporates the lagged time dependent statin vari-
able. All statistical analyses were conducted in SAS Version 9.3 (SAS Institute in Cary, NC).
Results
Of 7813 primary pancreatic adenocarcinoma cases, 20% were 85 years or older, 41% were
male, and 78% were of White race (Table 1). Cancer was staged as local or regional in 36% of
the population. Surgical resection was performed on 11% of the cases, and 21% of the cases had
chemotherapy. The prevalence of surgical management and chemotherapy are comparable to
previous publication on pancreatic cancer patients represented in SEER-Medicare [11]. Thir-
teen percent of the cases had evidence of ICD9 diagnoses of overweight/obesity, 67% dyslipide-
mia, and 48% diabetes. A majority of the study population (93%) died in the follow-up period
(median follow-up 3.1 months, interquartile range [IQR]: 1.3, 8.6).
Statin treatment after cancer diagnosis was reported in 31% of the patient population
(Table 1). Patients who used statin after cancer diagnosis were younger, and more likely to
have local/regional disease, lower grade, and smaller tumor size. Statin users were also more
likely to receive surgical resection, chemotherapy, and radiotherapy; and were more likely to be
diagnosed with obesity, dyslipidemia, and diabetes. Among PDAC patients who used statin
after cancer diagnosis, simvastatin was most commonly prescribed (48%), followed by atorva-
statin (25%), and lovastatin (18%) (Table 2). Most patients were on lipophilic statins, of high
potency and low-to-moderate dose. The proportion of follow-up days on statin did not vary by
statin intensity (57% in low, 56% in moderate, and 55% in high intensity statin users; data not
shown). The median survival time was significantly longer among patients who used statin
after cancer diagnosis (4.7 months, interquartile range: 1.9–11.7) compared to those who were
never prescribed a statin after cancer diagnosis (2.4 months, interquartile range: 1.1–7.3).
Table 3 presents the results of the association of survival with statin use after cancer diagno-
sis in PDAC patients from several modeling approaches. The estimated HR of 0.76 for a time-
dependent statin variable from model 2 was weaker compared to the HR of 0.69 estimated for a
non-time-dependent statin variable in model 1, showing that the assumptions for the non-
time-dependent effect of statin, including immortal time bias, had exaggerated the statin-sur-
vival association in model 1 (Table 3). The association of statin use after PDAC diagnosis and
survival remained significant after adjusting for all potential confounders considered
(HR = 0.79, 95% CI 0.75, 0.83) (Table 3). When we evaluated the association of statin exposure
lagged by 2 months with survival, an approach that is less prone to bias from reverse causation,
we observed an attenuated and non-significant association between statin use and survival
(HR = 0.94, 95% CI 0.75, 1.01). This analysis, which was limited to those who survived for at
least 2 months (n = 4705), showed that end of life variation in statin prescription fills had bi-
ased our results.
Important heterogeneity in the association between statin use after cancer diagnosis and
survival in PDAC patients was observed in stratified analyses. We found an inverse association
of statin use after cancer diagnosis with survival in those with grade I or II cancer (HR = 0.79,
95%CI 0.67, 0.93), but not in those with grade III or IV cancers (HR = 1.07, 95%CI 0.89, 1.29; p
for interaction = 0.02). Furthermore, patients with chronic pancreatitis were more likely to ex-
perience a survival advantage associated with statin use cancer diagnosis (HR = 0.75, 95%CI
0.56, 0.99) compared to those without chronic pancreatitis (HR = 0.96, 95%CI 0.90, 1.03; p for
Statin and Pancreatic Cancer Survival
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interaction = 0.03). Statin use after cancer diagnosis was also associated with survival in those
who underwent a pancreatectomy (HR = 0.80, 95%CI 0.66, 0.97) versus no surgery, in those di-
agnosed with COPD (HR = 0.89, 95%CI 0.80, 1.00) versus no COPD, and in those who had
Table 1. Distribution of demographic, clinical and comorbid characteristics by statin treatment after diagnosis with pancreatic adenocarcinoma.
Variables Category Total (n = 7813) Not exposed to statin
after cancer
diagnosis n = 5357
(69%)
Exposed to statin
after cancer
diagnosis n = 2456
(31%)
P-value
n column % n column % n column %
Age <0.0001
65–74 2932 (38) 1939 (36) 993 (40)
75–84 3311 (42) 2230 (42) 1081 (44)
85+ 1570 (20) 1188 (22) 382 (16)
Sex 0.79
Male 3212 (41) 2197 (41) 1015 (41)
Female 4601 (59) 3160 (59) 1441 (59)
Race 0.001
White 6121 (78) 4207 (79) 1914 (78)
Black 818 (10) 590 (11) 228 (9)
Other 874 (11) 560 (10) 314 (13)
Neighborhood median income 0.0002
<$35,000 OR unknown* 1986 (25) 1411 (26) 575 (23)
$35,000-$49,999 2508 (32) 1760 (33) 748 (30)
$50,000-$74,999 2279 (29) 1517 (28) 762 (31)
$75,000 + 1040 (13) 669 (12) 371 (15)
Summary stage <0.0001
Localized/Regional 2832 (36) 1837 (34) 995 (41)
Distant 4331 (55) 3039 (57) 1292 (53)
Stage unavailable 650 (8) 481 (9) 169 (7)
Grade <0.0001
1 or 2 1150 (15) 718 (13) 432 (18)
3 or 4 954 (12) 640 (12) 314 (13)
Unknown 5709 (73) 3999 (75) 1710 (70)
Tumor size <0.0001
<5cm 3986 (51) 2601 (49) 1385 (56)
> = 5cm 1471 (19) 1030 (19) 441 (18)
Unknown 2356 (30) 1726 (32) 630 (26)
Resection 842 (11) 500 (9) 342 (14) <0.0001
Chemotherapy 1635 (21) 998 (19) 637 (26) <0.0001
Radiation 606 (8) 368 (7) 238 (10) <0.0001
Obesity 990 (13) 647 (12) 343 (14) 0.02
Chronic pancreatitis 497 (6) 347 (6) 150 (6) 0.53
COPD 2947 (38) 2067 (39) 880 (36) 0.02
Dyslipidemia 5259 (67) 3389 (63) 1870 (76) <0.0001
Diabetes/IGT 3729 (48) 2370 (44) 1359 (55) <0.0001
*Unknown income group comprise less than 2% in this category.
Numbers are not reported due to small N.
doi:10.1371/journal.pone.0121783.t001
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not been treated with statin prior to cancer diagnosis (HR = 0.80, 95%CI 0.63, 1.00) versus
those with previous treatment with statin. The differenced in HRs by the latter three potential
effect modifiers were marginally significant (Table 4). No significant difference in the
Table 2. Description of statin use after cancer diagnosis by name, lipophilicity, potencity, intensity, duration, consistency of use (n = 2456).
Variables Category n column %
Statin name*
Atorvastatin 605 (25)
Fluvastatin 16 (1)
Lovastatin 452 (18)
Pravastatin 171 (7)
Rosuvastatin 116 (5)
Simvastatin 1184 (48)
Statin lipophilicity*
Hydrophilic 284 (12)
Lipophilic 2199 (90)
Statin potency*
High 1864 (76)
Low 639 (26)
Statin intensity
Low 400 (16)
Moderate 1663 (68)
High 393 (16)
Statin use pre-cancer diagnosis
No 158 (6)
Yes 2298 (94)
* Categories are not mutually exclusive for these variables
doi:10.1371/journal.pone.0121783.t002
Table 3. Relative hazard of death for statin use after cancer diagnosis vs. no statin use (n = 7813).
Model HR (95%) P-value
Model 1: Unadjusted model using statin as a non-time-dependent variable 0.69 (0.66,
0.72)
<0.0001
Model 2: Unadjusted model using statin as a time-dependent variable (removes
immortal time bias)
0.76 (0.72,
0.80)
<0.0001
Model 3: Model 2 + age, sex, race, neighborhood income adjustment 0.79 (0.75,
0.83)
<0.0001
Model 4: Model 3 + stage, grade, tumor size 0.80 (0.76,
0.84)
<0.0001
Model 5: Model 4 + resection, radiation and chemotherapy 0.80 (0.76,
0.84)
<0.0001
Model 6: Model 5 + obesity, dyslipidemia, diabetes/IGT, chronic pancreatitis
and COPD
0.79 (0.75,
0.93)
<0.0001
Model 7: Modeling statin as a time-dependent variable that lags by 2 months
(removes reverse causation, restricts population to >2 month survivors)
0.94 (0.89,
1.01)
0.08
HR = hazard ratio for statin use; IGT = impaired glucose tolerance, COPD = chronic obstructive
pulmonary disease
doi:10.1371/journal.pone.0121783.t003
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association of statin use with survival was observed by testing for interaction with age, summa-
ry stage, tumor size, chemotherapy, dyslipidemia, or diabetes.
When each type of statin used after cancer diagnosis was investigated for independent ef-
fects in the same model, only simvastatin treatment was associated with a significantly lower
hazard of death compared to no statin treatment (HR = 0.91, 95%CI 0.84, 0.99) (fluvastatin
was not considered due to small cell size (n = 16)) (Table 5). When separated by lipophilicity,
Table 4. Multivariable-adjusted association between statin use after diagnosis with pancreatic cancer and overall survival in substrata of
covariates.
Variables Category Adjusted HR (95% CI) for death comparing statin use vs.
non-use
p-
value
P-value for
interaction
Age 0.86
65–74 0.94 (0.85, 1.04) 0.23
75–84 0.93 (0.84, 1.03) 0.15
85+ 0.96 (0.81, 1.15) 0.68
Summary stage 0.34
Localized/
Regional
0.91 (0.82, 1.00) 0.051
Distant 0.99 (0.90, 1.08) 0.75
Grade 0.02
1 or 2 0.79 (0.67, 0.93) 0.004
3 or 4 1.07 (0.89, 1.29) 0.45
Tumor size 0.38
<5cm 0.94 (0.86, 1.02) 0.14
5cm 0.88 (0.75, 1.03) 0.11
Resection 0.054
Yes 0.80 (0.66, 0.97) 0.02
No 0.96 (0.90, 1.03) 0.26
Chemotherapy 0.72
Yes 0.93 (0.82, 1.04) 0.21
No 0.96 (0.88, 1.03) 0.25
Dyslipidemia 0.52
Yes 0.95 (0.88, 1.03) 0.24
No 0.95 (0.84, 1.07) 0.41
Diabetes/IGT 0.99
Yes 0.92 (0.84, 1.02) 0.1
No 0.95 (0.97, 1.04) 0.25
Chronic pancreatitis 0.03
Yes 0.75 (0.56, 0.99) 0.04
No 0.96 (0.90, 1.03) 0.15
COPD 0.07
Yes 0.89 (0.80, 1.00) 0.046
No 0.98 (0.91, 1.06) 0.66
Statin use pre cancer
diagnosis
0.11
Yes 0.97 (0.84, 1.11) 0.65
No 0.80 (0.63, 1.00) 0.048
.
Note: Stratified analysis in which statistically significant associations of statin use after cancer diagnosis with survival are highlighted in bold type
doi:10.1371/journal.pone.0121783.t004
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neither hydrophilic nor lipophilic statin was associated with survival. When separated by po-
tency, those who were on high potency statin experienced significantly decreased hazard of
death (HR = 0.93, 95% 0.86, 1.00). Increasing intensity of statin dose was not correlated with
stronger inverse associations. Rather, those treated with low dose statin were more likely to
show a benefit by statin (HR = 0.85, 95%CI 0.75, 0.97) (Table 5).
Discussion
Our study is the first population-based analysis of the association of statin and pancreatic can-
cer survival and is the first study to examine how the outcomes vary by specific statin type and
intensity of use. Compared to those who did not use statins, the median survival in patients
who used statin after cancer diagnosis was increased by 1.3 months overall. Accounting for im-
mortal time between cancer diagnosis and statin treatment, reverse causation, as well as multi-
ple demographic, clinical and comorbid factors, the overall association between statin use after
cancer diagnosis and survival in PDAC patients was attenuated to a non-significant relation-
ship, although patients on simvastatin, and those on high potency statins (simvastatin, rosuvas-
tatin, atorvastatin) still showed a significant 7–9% reduction in rate of death. We found no
dose-response association with greater intensity of statin dose; the use of lower intensity statins
showed a modestly stronger association with survival which was not attributable to more
consistent use.
While the overall associations on statin use after cancer diagnosis and survival was not sig-
nificant, important differences in the statin-survival associations by grade, resection, chronic
pancreatitis and COPD were found. Statin use after cancer diagnosis showed an association
with survival in those who had grade I/II tumors and in those who had underwent a resection,
but not in patients with higher grade tumors and those who did not undergo a resection. This
finding may have resulted from the ability of statin to prevent the regrowth of well-differentiat-
ed pancreatic tumor, which occurs in a majority of those with a resection. We also found that
the statin-survival association was significant in those with chronic pancreatitis and people
with COPD, but not in those without these conditions. This suggests that statin may have an
Table 5. Multivariate association of survival with name, lipophilicity, potency, intensity of statin use after diagnosis of pancreatic
adenocarcinoma.
Variables Category adjusted HR (95%) for death P-value
Statin name
Atorvastatin vs. no statin 0.97 (0.87, 1.09) 0.59
Lovastatin vs. no statin 0.96 (0.85, 1.08) 0.48
Pravastatin vs. no statin 1.07 (0.88, 1.30) 0.53
Rosuvastatin vs. no statin 0.98 (0.79, 1.23) 0.87
Simvastatin vs. no statin 0.91 (0.84, 0.99) 0.03
Statin type
Hydrophilic vs. no statin 1.02 (0.87, 1.18) 0.85
Lipophilic vs. no statin 0.94 (0.88, 1.01) 0.08
Statin potency
High potency vs. no statin 0.93 (0.86, 1.00) 0.035
Low potency vs. no statin 0.99 (0.89, 1.10) 0.8
Statin intensity
Low vs. no statin 0.85 (0.75, 0.97) 0.02
Moderate vs. no statin 0.97 (0.90, 1.04) 0.35
High vs. no statin 0.97 (0.84, 1.11) 0.65
doi:10.1371/journal.pone.0121783.t005
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effect on tumors affected by heavy drinking, a major risk factor for chronic pancreatitis, and
smoking, a major risk factor for COPD, although the mechanisms are unknown. Importantly,
we found that statin use after cancer diagnosis was associated with survival in those with no ex-
posure to statin prior to cancer diagnosis, but not in those with prior statin exposure. It is con-
ceivable that statin treatment after cancer diagnosis may have a greater impact on statin-naïve
tumors that are sensitive to the molecular effects of statin, whereas tumors that arose in pa-
tients already receiving statins may have been selected for statin resistance before diagnosis.
That statin has a specific impact in those with grade I/II cancers and in those with no previous
exposure to statin suggests that there are specific tumor subtypes that likely will respond to
statin. Genomic and transcriptomic studies demonstrate that PDAC is a highly heterogeneous
cancer type [12], with molecular subtypes that vary in their response to existing therapies [13].
Molecular epidemiologic studies that integrate genetic information at the tumor level with clin-
ical data will help us identify patients who may benefit from statin treatment.
Our study results do not confirm the findings of a Japanese study that showed longer surviv-
al with statin use among patients with locally advanced or metastatic pancreatic cancer who
underwent chemotherapy [5]. The association of statin with pancreatic cancer survival found
in the Japanese study was specific to those with diabetes. We examined the potential interaction
between statin use after cancer diagnosis and diabetes, but did not find that the impact on sur-
vival varied by diabetes status. The two studies differed importantly in methodology. We ad-
justed for immortal time bias and reverse causation, while the Japanese study did not consider
the influence of these biases. Furthermore, our studies were different in that all patients in our
study population were elderly, while half of the Japanese study population was under the age of
66. It is possible that the non-diabetic patients were more similar to diabetic patients in this el-
derly population than in a younger population who have more beta cells [14]. Similar to our
null finding in those treated with chemotherapy and those with distant cancer type, a recent
clinical trial of simvastatin in gemcitabine-treated advanced pancreatic cancer patients found
no effect of a 3-week regimen of simvastatin on progression-free or overall survival [6].
A wealth of in vivo and in vitro evidence for the anti-cancer properties of statin supports the
therapeutic potential of statin against pancreatic cancer. The inhibition of HMG-CoA reduc-
tase by statin results in a decreased production of isoprenoids (e.g. farnesyl pyrophostate), nec-
essary post-translational modifiers of Ras and Rho proteins. Prenylation is required for
anchoring Ras to the membrane and subsequent transduction of extracellular growth factor
signals to effector pathways essential for cell cycle progression, growth, and survival of cancer
cells [4]. For pancreatic cancer, in which oncogenic mutation in K-Ras is common [15], statin
could have a particularly pronounced effect through modifying K-Ras activity. Statin is also
known to inhibit the membrane association of Rho proteins that are involved in cell adhesion,
cell motility, and invasion [4, 16]. In step with these molecular effects, statin treatment has
been shown to prevent pancreatic cancer cell invasion in vitro and metastasis to the liver in
vivo [16]. Statin also has been shown to induce autophagy, potentially through depletion of ger-
anylgeranyl diphosphate and activation of AMP kinase [17] and autophagic cell death in some
cancer cell lines [18], although the role of autophagy in pancreatic cancer is contradictory [19–
21]. A recent animal-model study [21] demonstrated that induction of autophagy in the pres-
ence of TP53 mutation limits the growth of tumors. Future studies investigating the heteroge-
neous effect of statin by common somatic mutations in KRAS, TP53, CDK2N2A, SMAD4, are
warranted to elucidate the mechanisms by which statin could impact tumor’s growth, invasion
and metastasis.
Despite several strengths of the SEER-Medicare data, including a comparatively large sam-
ple size, generalizability to the U.S. population and detailed information on prescriptions, our
study was limited by the lack of laboratory data on cholesterol, triglyceride, and glucose levels
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that would have informed the extent of metabolic disturbances in the population. Compared to
pancreatic cancer patients exposed to low intensity statins, high intensity statin users were
more likely to have obesity, dyslipidemia and diabetes, indicating more severe metabolic distur-
bances in this population; thus having laboratory-based data could have reduced residual con-
founding by severity of metabolic disease. We also lacked more granular data on cancer
progression, which could have confounded the association between statin use and death, given
that statin treatment may be withheld or discontinued in patients with short expected survival
time. When we adjusted for such reverse causation by incorporating a lagged statin variable
that effectively excludes the 2 months exposure period before death, the statin effect on survival
was greatly attenuated. This demonstrates that it is important to consider how prescription
drug treatment after cancer diagnosis is influenced by poor prognosis. Even with the adjust-
ment for reverse causation, there still remains a possibility that the patients with severe symp-
toms and worse prognosis were unable to fill their prescriptions, or that statin was withheld in
persons with metastases to the liver due to risk of transaminitis [22]. However, we saw the ef-
fect of statin treatment in those with low grade, resected cancers, who likely experienced less se-
vere symptoms and faced a better prognosis. We lacked individual-level data on the
socioeconomic status of cancer patients, which could have confounded the relationship be-
tween statin use and death. This is critical to consider, given that socioeconomically disadvan-
taged patients are less likely to take statin [23]. Because we restricted the population to those
continuously enrolled in Medicare Parts B and D, which require monthly premiums, we believe
that statin users and non-users would be comparable with respect to access to prescription
drugs.
In conclusion, we found that statin treatment is associated with enhanced survival in pa-
tients with pancreatic adenocarcinoma. Residual confounding by factors related to healthy be-
havior, statin use, and survivorship, however, could not be excluded due to limitations of the
claims-based data. Furthermore, our SEER-Medicare analysis was limited to elderly patients
enrolled in Medicare, who are less likely to be offered surgery or more likely to refuse surgery
compared to a younger population enrolled in private insurance companies [11]. This subopti-
mal management, combined with greater comorbid conditions, would have led to an even
shorter survival than in a younger population, which limits the generalizability of the study.
In light of the potential benefits of statin and its widespread use, a clinical trial of statin in
pancreatic cancers is warranted in those with resected, low-grade pancreatic cancer. If proven
beneficial, statin could be a novel and readily implementable cancer intervention for low-
grade, resectable pancreatic cancer types for which treatment options are few.
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